Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

NCT02013609 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

MDD

Interventions

DRUG: Brexpiprazole

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]